Last Updated : October 30, 2024
Details
FilesGeneric Name:
Nivolumab and Ipilimumab
Project Status:
Complete
Therapeutic Area:
Melanoma (Skin)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0347-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
In combination, for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma when patients progress during or within 6 months of adjuvant PD-1 therapy.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | November 09, 2023 |
|---|---|
| Call for patient/clinician input closed | January 08, 2024 |
| Call for industry input open | November 09, 2023 |
| Call for industry input closed | January 08, 2024 |
| Submission received | October 24, 2023 |
| Review initiated | October 25, 2023 |
| Expert committee meeting (initial) | May 10, 2024 |
| Draft recommendation posted for stakeholder feedback | June 06, 2024 |
| End of feedback period | June 20, 2024 |
| Final recommendation posted | August 01, 2024 |
| CADTH review report(s) posted | August 01, 2024 |
Files
Last Updated : October 30, 2024